Navigation Links
Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007

mean change in serum creatinine in patients treated with the highest dose of KW-3902 compared to a 0.2 milligram per deciliter mean increase, or worsening, in participants receiving placebo. These data are consistent with prior findings and indicate that KW-3902 appears to have a persistent effect on renal function. To date, no other vasodilator has demonstrated the selective renal vasodilation attribute of KW-3902 that is critical for preserving renal function.

About Congestive Heart Failure

Congestive heart failure (CHF) is a widespread and debilitating disease most often caused by a weakening or stiffening of the heart muscle, which leads to a progressive loss in the heart's ability to pump blood effectively throughout the body. There are nearly five million people in the United States with CHF, according to the American Heart Association (AHA). With the aging population and more patients surviving the early stages of cardiovascular diseases, the prevalence of CHF is increasing. Approximately 550,000 new cases of CHF are reported in the United States each year, according to the AHA.

About NovaCardia

NovaCardia is a clinical-stage pharmaceutical company focused on developing drugs to treat major cardiovascular diseases that are underserved by existing therapies. The company has two compounds in clinical development, KW-3902 for congestive heart failure and K-201 (JTV-519) for atrial fibrillation.

NovaCardia cautions you that statements included in this press release that are not a description of historical facts, including implied statements relating to future outcomes of clinical trials, may be forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in NovaCardia's business including, without limitation, risks related to difficulties or delays in, testing, obtaining regulatory approval, producing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/4/2015)... 4, 2015   HeartWare International, Inc . (NASDAQ: ... support technologies that are revolutionizing the treatment of advanced heart ... , is scheduled to present at the Bank of America ... Vegas on Thursday, May 14, 2015, at 10:00 ... of the Company,s presentation at the conference will be available ...
(Date:5/4/2015)... 2015 MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, today ... the Company,s investigational drug candidate ME-344 in cancer ... with a tyrosine-kinase inhibitor (TKI). In addition, a ... potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex ...
(Date:5/4/2015)... 2015 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... for quarter ending March 31, 2015 after market ... host a conference call that day at 5:00 ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
... The University HealthSystem Consortium (UHC) today announced an agreement with Centurion Service ... services. The contract was effective on February 1, 2010 . , ... Centurion, the world,s largest medical auction house with ... assists UHC members in the setup and management of their surplus asset programs ...
... (NYSE: ABT ) will present at the 26th Annual Sanford Bernstein ... York City .  Miles D. White, chairman and chief executive officer, will make ... , , , ... presentation will be accessible through Abbott,s Investor Relations Web site at www.abbottinvestor.com ...
Cached Medicine Technology:University HealthSystem Consortium Selects Centurion Service Group for Equipment and Asset Liquidation Services 2
(Date:5/4/2015)... San Diego Fertility Center (SDFC) ... brand new, 13,700 square foot facility scheduled to open ... not only provide fertility treatment and services for the ... and educational events to a number of local and ... door to their current Carmel Valley/Del Mar location and ...
(Date:5/4/2015)... May 04, 2015 Dr. Benjamin Stong ... proudly offers the latest non-surgical double-chin eliminator. Dr. ... plastic surgeon in Atlanta to offer Kybella treatments ... be injected specifically under the chin, promising to safely ... Before Kybella, patients who sought immediate solutions for their ...
(Date:5/4/2015)... May 04, 2015 Unlike some camps, the Nike ... knowledge. The goal is to educate first and train second, ... This ensures that the young runners are building the knowledge base ... few of the topics covered include Effort Based Training, Running Heroes, ... used to be? This is not a camp where kids ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased to ... America’s Best Dentist Award, given by the National Consumer ... dentist is a reflection of his vast experience in ... for his patients. , Each year, the National Consumer ... field. These nominees are dentists who have exceptionally high ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sylvia Hawthorn-Deppen shared ... hopes that it would remind others in similar situations that ... Recovery from Chronic Pain and Discovery of New Energy” (published ... a new audience via a renewed press campaign. , “I ... debilitating pain ,” Hawthorn-Deppen says. “As an adolescent I ...
Breaking Medicine News(10 mins):Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2
... Teens Still Feel Targeted By Tobacco Advertising and Find ... Kids across Delaware,will rally against tobacco on April 2 ... 13th annual Kick Butts Day, sponsored by the,Campaign for ... (for a list of local events, go to ...
... By Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... against tobacco on April 2 as they join thousands ... Day, sponsored by the,Campaign for Tobacco-Free Kids. Hundreds of ... local events, go to, http://www.kickbuttsday.org/events )., This year, ...
... (OTC,Bulletin Board: BNLB) is pleased to announce that sales ... at the beginning of this year, have,exceeded the company,s ... 2008., Fusion,s 6+ Hour Energy Shot was first ... past November, where it was voted,"Best Tasting Shot". Fusion ...
... N.C., March 27 Marshall Erdman &,Associates ... company by,"Modern Healthcare,s" 2008 Construction & Design ... the healthcare industry; it,examines year-over-year sales, contracted ... in business and number of architects, engineers,and ...
... 27 Biotest Pharmaceuticals,Corporation, a leading developer ... announcement that a Hepatitis B Immune Globulin,Intravenous ... received,Orphan Drug designation by the U.S. Food ... hepatitis B recurrence following orthotopic liver,transplantation., ...
... major licensing deals like the one his company recently ... front of mind for rising Australian biotechnology star, Antisense ... when he meets with leading industry figures in the ... scientists chosen from a highly competitive field of candidates ...
Cached Medicine News:Health News:Delaware Kids 'Kick Butts' on April 2 2Health News:Delaware Kids 'Kick Butts' on April 2 3Health News:Georgia Kids 'Kick Butts' on April 2 2Health News:Georgia Kids 'Kick Butts' on April 2 3Health News:Bond Laboratories' First Quarter Fiscal 2008 Sales Exceeding Internal Projections 2Health News:'Modern Healthcare' Names Marshall Erdman Nation's Top Design-Build Company 2Health News:Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement 2Health News:Antisense therapeutics scientist out to pull more big deals 2
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
... Cryo System is the first in portability and performance. ... surgeons who need a flexible, portable system with the ... CTU attaches easily to an "E" size tank and ... cryo to where it is needed.,The CTU Travel Case ...
... an easy-to-use, workflow-based system designed to save you ... of the SleepWorks software and either the Connex ... systems can be used for a complete range ... full EEG recording - and have superior signal ...
... Merci Retrieval System is made up of ... Merci Microcatheter and the Merci Balloon Guide ... Once the location of the clot has ... Guide Catheter is inserted through a small ...
Medicine Products: